Clinical Trial Update: Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer

View source ↗

Summary

This clinical trial evaluates subcutaneous pyrotinib combined with trastuzumab versus intravenous administration for HER2-positive early breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Jiangsu Famous Medical Technology Co., Ltd. | Conditions: HER2+ Breast Cancer | Status: NOT_YET_RECRUITING